Harrow Secures J-Code for IOPIDINE 1%, Clearing Reimbursement Hurdle
Event summary
- Harrow's IOPIDINE 1% (apraclonidine hydrochloride ophthalmic solution) assigned permanent J-Code (J2374) by CMS, effective July 1, 2026.
- J-Code enables direct reimbursement for in-office administration, removing a key adoption barrier.
- IOPIDINE 1% is the only FDA-approved product to prevent intraocular pressure (IOP) spikes post-laser procedures.
- Over 1.5 million ophthalmic laser procedures performed annually in the U.S., a growing market.
The big picture
The J-Code assignment for IOPIDINE 1% aligns with broader industry trends toward value-based care and streamlined reimbursement for in-office procedures. Harrow's move positions it to capture a larger share of the expanding ophthalmic laser procedure market, where preventing IOP spikes is critical for patient outcomes and cost efficiency. The strategic play underscores the importance of reimbursement infrastructure in driving product adoption.
What we're watching
- Adoption Pace
- Whether the J-Code designation will accelerate IOPIDINE 1% integration into standard glaucoma and laser procedure workflows.
- Market Penetration
- How effectively Harrow can capitalize on the growing number of in-office laser procedures to expand IOPIDINE 1% usage.
- Competitive Response
- Whether competitors will introduce similar reimbursed solutions, potentially pressuring IOPIDINE 1%'s market share.
Related topics